logo
Cipher Pharmaceuticals' Natroba granted Medicaid preferred status in Illinois

Cipher Pharmaceuticals' Natroba granted Medicaid preferred status in Illinois

Cipher Pharmaceuticals (TSX:CPH), a profitable specialty pharma company, reports that its Natroba treatment for scabies and head lice has been upgraded to preferred status by the state of Illinois
Concurrently, the state has downgraded Natroba's main competitor, Permethrin 5%, to non-preferred status
Cipher is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology
Cipher Pharmaceuticals stock has added 50.23 per cent year-over-year and 1,322.22 per cent since 2020
Cipher Pharmaceuticals (TSX:CPH), a profitable specialty pharma company, reports that its Natroba treatment for scabies and head lice has been upgraded to preferred status by the state of Illinois. Concurrently, the state has downgraded Natroba's main competitor, Permethrin 5%, to non-preferred status.
According to Tuesday's news release, the changes mean that 'all Medicaid treatments for scabies and Permethrin 5% prescriptions in the state must first step through Natroba being the preferred treatment in Illinois.'
The company believes that recent studies showing parasitic resistance to Permethrin played a determining factor in the updated preferred drug listing. See work by Rinaldi and Simonart for further reference.
Cipher has delivered positive net income over the past five fiscal years, with a high of US$26.64 million in 2022, and grew revenue by 58 per cent in 2024 thanks to increasing market share and the acquisition of Natroba. Investors have collected an over 1,300 per cent return since 2020. Leadership insights
'The medical decision made by the state of Illinois is just another example of the effectiveness of Natroba (Spinosad) and what clear growth potential for the product remains ahead of us,' Craig Mull, Cipher Pharmaceuticals' interim chief executive officer, said in a statement. 'We believe it is only a matter of time until more state pharmacy directors require step-through of Natroba representing the standard of care in the treatment of scabies and head lice. We are in active discussions with other U.S. states to build upon this recent success, and we continue to believe there is significant potential outside the U.S. to out-license Natroba whereby lice resistance to Permethrin-based products is a pervasive worldwide issue and whereby Natroba fills an unmet need.' About Cipher Pharmaceuticals
Cipher is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The company markets its products in Canada, South America and the United States.
Cipher Pharmaceuticals stock (TSX:CPH) is up by 3.31 per cent on the news trading at C$12.80 as of 10:01 am. The stock has added 50.23 per cent year-over-year and 1,322.22 per cent since 2020.
Join the discussion: Find out what everybody's saying about this pharmaceuticals stock on the Cipher Pharmaceuticals Inc. Bullboard and check out Stockhouse's stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top photo: Cipher Pharmaceuticals)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca's New Trial: A Potential Game-Changer in Prostate Cancer Treatment
AstraZeneca's New Trial: A Potential Game-Changer in Prostate Cancer Treatment

Globe and Mail

time7 minutes ago

  • Globe and Mail

AstraZeneca's New Trial: A Potential Game-Changer in Prostate Cancer Treatment

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical trial titled A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer. The study aims to assess the safety and tolerability of the drugs AZD2284, AZD2287, and AZD2275 in treating this aggressive form of prostate cancer. The trial is testing three drugs: AZD2284, AZD2287, and AZD2275, all administered via intravenous methods. AZD2284 is the primary focus, with the goal of determining its optimal dosing and efficacy in conjunction with the other two drugs. This non-randomized, open-label study follows a sequential intervention model. It is primarily focused on treatment, with no masking involved, allowing for direct observation of the drug effects. The study began on March 10, 2025, with the latest update submitted on July 22, 2025. These dates are crucial as they indicate the study's progress and the timeline for potential results. This study's update could influence AstraZeneca's stock performance positively, as successful results may enhance investor confidence and market position in the oncology sector. Competitors in the prostate cancer treatment market will be closely monitoring these developments. The study is currently recruiting, with further details available on the ClinicalTrials portal.

AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment
AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment

Globe and Mail

time7 minutes ago

  • Globe and Mail

AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is conducting a phase 1 clinical study titled A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AZD0486 in patients with B-cell non-Hodgkin lymphoma. The intervention being tested is AZD0486, a bispecific antibody designed to engage T-cells and target CD19 on tumor cells, facilitating T cell-mediated destruction of malignant B cells. It is administered intravenously in a structured dosing schedule. This interventional study follows a sequential intervention model with no masking, focusing primarily on treatment. Participants receive increasing doses of AZD0486, with safety and efficacy monitored throughout the study. The study began on March 2, 2021, and is currently recruiting. The last update was submitted on July 22, 2025. These dates are crucial for tracking the study's progress and ensuring timely updates to stakeholders. The ongoing study may influence AstraZeneca's stock performance and investor sentiment, as successful outcomes could enhance the company's oncology portfolio. Investors should also consider the competitive landscape in the B-cell lymphoma treatment market. The study is ongoing, with further details available on the ClinicalTrials portal.

AstraZeneca's Latest Study: Evaluating Ceralasertib's Impact on Cancer Drug Pharmacokinetics
AstraZeneca's Latest Study: Evaluating Ceralasertib's Impact on Cancer Drug Pharmacokinetics

Globe and Mail

timean hour ago

  • Globe and Mail

AstraZeneca's Latest Study: Evaluating Ceralasertib's Impact on Cancer Drug Pharmacokinetics

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical study titled 'A Phase I, Open-label, Fixed-sequence Study to Evaluate the Effect of Ceralasertib on Pharmacokinetics of Drug X, Drug Y and Drug Z in Participants With Advanced Solid Tumours.' The study aims to assess how ceralasertib affects the pharmacokinetics of three other drugs in patients with advanced solid tumors, potentially offering new insights into cancer treatment. The intervention involves administering ceralasertib, alongside Drugs X, Y, and Z. Ceralasertib is given twice daily over a week, with single doses of the other drugs administered on specific days to evaluate interactions. This open-label study follows a single-group assignment model with no masking, focusing on treatment as its primary purpose. It includes multiple visits and wash-out periods to ensure accurate results. The study began on May 21, 2025, with the latest update submitted on July 22, 2025. These dates are crucial for tracking the study's progress and ensuring transparency. For investors, this study could influence AstraZeneca's stock performance by potentially expanding its oncology portfolio. The collaboration with Parexel highlights a strategic partnership that could enhance research capabilities, impacting investor sentiment positively. Competitors in the oncology sector may also be closely monitoring these developments. The study is currently recruiting, with further details available on the ClinicalTrials portal.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store